Insulin Analogs: A Century of Peptide Drug Innovation

The history of insulin from discovery to modern analogs — how peptide engineering transformed diabetes treatment.

Filed under approved medicines, written for patient-consumer, clinician, researcher, investor, evidence level A.

Not medically reviewed. Last updated 2026-03-10. Nothing here is medical advice.

Insulin, discovered in 1921, was one of the first peptide therapeutics and remains one of the most important. The evolution from animal-derived insulin to recombinant human insulin to modern analogs illustrates the power of peptide engineering.

Timeline of Innovation

• **1921**: Banting and Best isolate insulin from pancreatic extracts
• **1922**: First human patient treated with insulin
• **1955**: Sanger determines insulin's amino acid sequence (Nobel Prize 1958)
• **1978**: Recombinant human insulin produced via E. coli
• **1982**: Humulin (recombinant human insulin) approved by FDA
• **1996**: Insulin lispro (Humalog) — first rapid-acting analog
• **2000**: Insulin glargine (Lantus) — first long-acting analog
• **2015+**: Biosimilar insulin products enter the market

Types of Insulin Analogs

Rapid-Acting

Modified to reduce self-association and speed absorption: lispro, aspart, glulisine.

Long-Acting

Engineered for extended duration: glargine, detemir, degludec.

Ultra-Long-Acting

Insulin degludec provides a 42+ hour duration of action through multi-hexamer depot formation.

Peptide Engineering Principles

Insulin analog design demonstrates key peptide modification strategies:

• Amino acid substitutions to alter aggregation
• Acylation to extend half-life (detemir, degludec)
• pH-dependent solubility for depot formation (glargine)

Global Impact

Over 500 million people worldwide have diabetes. Insulin analogs have significantly improved glycemic control and quality of life.

This article is for educational purposes only.

More guides: All guides, Safety centre, Peptide library.